Andrea R. Lim
Research Subjects
Andrea R. Lim has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Bryan Grogan
Pfizer, Inc., Bothell, Washington
22 shared publications - Christopher M. Carosino
Pfizer, Inc., Bothell, Washington
22 shared publications - Cristina L. Abrahams
Sutro BioPharma, South San Francisco, California
22 shared publications - Daniel Diolaiti
Memorial Sloan Kettering Cancer Center 9 Bothell
22 shared publications - Devra J. Olson
Pfizer, Inc., Bothell, Washington
22 shared publications - Haley D. Neff-LaFord
Pfizer, Inc, Bothell, Washington
22 shared publications
Latest Publications
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
CD25 expression in the microenvironment of solid tumor indications.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
CD25 expression in the microenvironment of solid tumor indications.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S3 shows the identification of affinity-detuned Clone123-YH98A.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S3 shows the identification of affinity-detuned Clone123-YH98A.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S4 shows that PF-08046032 maintains specific binding and internalization to CD25+ cells.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S4 shows that PF-08046032 maintains specific binding and internalization to CD25+ cells.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S12 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S12 shows the PK/PD analysis of PF-08046032 in cynomolgus monkeys.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S12 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S12 shows the PK/PD analysis of PF-08046032 in cynomolgus monkeys.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Percentage of Tumor Growth Inhibition (%TGI) for lymphoma xenografts.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Percentage of Tumor Growth Inhibition (%TGI) for lymphoma xenografts.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
X50 values for PF-08046032 across a panel of CD25-expressing cell lines.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
X50 values for PF-08046032 across a panel of CD25-expressing cell lines.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
%TGI for syngeneic mouse models.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
%TGI for syngeneic mouse models.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S8 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S8 shows the effect of conjugating Clone123 with other payloads on Tregs and T cells.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S8 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S8 shows the effect of conjugating Clone123 with other payloads on Tregs and T cells.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S1 shows CD25 expression in Cancer.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors
Supplemental Figure S1 shows CD25 expression in Cancer.